A Phase 1b/2 Study to Evaluate the Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer
Phase of Trial: Phase I/II
Latest Information Update: 14 Nov 2019
Price : $35 *
At a glance
- Drugs VERU 111 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Veru Healthcare
- 16 Feb 2019 Trial design presented at the 2019 Genitourinary Cancers Symposium.
- 28 Jan 2019 Status changed from not yet recruiting to recruiting.
- 21 Nov 2018 Status changed from planning to not yet recruiting.